House Simple Resolution 242
116th Congress(2019-2020)
Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.
Introduced
Introduced in House on Mar 18, 2019
Origin Chamber
House
Type
Simple Resolution
Simple Resolution
A form of legislative measure introduced and potentially acted upon by only one congressional chamber and used for the regulation of business only within the chamber of origin. Depending on the chamber of origin, they begin with a designation of either H.Res. or S.Res. Joint resolutions and concurrent resolutions are other types of resolutions.
Bill Number
242
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
This resolution applauds the growth in research and development into new therapies for rare diseases and recognizes that significant research and development efforts and related investments are needed to develop therapies to treat and cure thousands of rare diseases for which no treatment options are currently available.
March 18, 2019
Sort by most recent
03/19/2019
Referred to the Subcommittee on Health.
03/18/2019
Referred to the House Committee on Energy and Commerce.
03/18/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 6:02:32 PM